Acute myeloid leukemia (AML) is characterized by impaired differentiation and indefinite
proliferation of abnormal myeloid progenitors. Although differentiating agents were deemed …

The direct targeting of chromatin-associated proteins is increasingly recognized as a
potential therapeutic strategy for the treatment of cancer. In this review, we discuss a …

In MLL1-rearranged AML (MLL1-r), the MLL1 fusion protein (MLLFP) causes dysregulated
expression of HOXA9, MEIS1, PBX3, MEF2C and CDK6 [1, 2]. HOXA9 and its co-factor …

Papain-like cysteine peptidases form a big and highly diverse superfamily of proteins
involved in many important biological functions, such as protein turnover, deubiquitination …

Abstract Exd/PBX, Hth/MEIS and PREP proteins belong to the TALE (three-amino-acid loop
extension) superclass of transcription factors (TFs) with an atypical homedomain (HD) …

Menin interacts with oncogenic MLL1-fusion proteins, and small molecules that disrupt these
associations are in clinical trials for leukemia treatment. By integrating chromatin-focused …

Adhesion molecules play essential roles in the homeostatic regulation and malignant
transformation of hematopoietic cells. The dysregulated expression of adhesion molecules …

Acute myeloid leukemia (AML) represents a genetically heterogeneous group of myeloid
neoplasms derived from early hematopoietic progenitors. Mutations in the NPM1 gene and …

Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia
(AML) in which leukemic blasts have megakaryocytic features. AMKL makes up 4-15% of …

Small molecules that target the menin-KMT2A protein-protein interaction (menin inhibitors)
have recently entered clinical trials in lysine methyltransferase 2A (KMT2A or MLL1) …